| Emerging role of exosomes in cancer progression and tumor microenvironment remodeling MDA Paskeh, M Entezari, S Mirzaei, A Zabolian, H Saleki, MJ Naghdi, ... Journal of hematology & oncology 15 (1), 83, 2022 | 247 | 2022 |
| Association of the epithelial–mesenchymal transition (EMT) with cisplatin resistance M Ashrafizadeh, A Zarrabi, K Hushmandi, M Kalantari, ... International journal of molecular sciences 21 (11), 4002, 2020 | 194 | 2020 |
| Regulation of Nuclear Factor-KappaB (NF-κB) signaling pathway by non-coding RNAs in cancer: Inhibiting or promoting carcinogenesis? S Mirzaei, A Zarrabi, F Hashemi, A Zabolian, H Saleki, A Ranjbar, ... Cancer Letters 509, 63-80, 2021 | 185 | 2021 |
| Long non-coding RNAs in the doxorubicin resistance of cancer cells S Ashrafizaveh, M Ashrafizadeh, A Zarrabi, K Husmandi, A Zabolian, ... Cancer Letters 508, 104-114, 2021 | 139 | 2021 |
| New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities M Ashrafizadeh, S Mirzaei, F Hashemi, A Zarrabi, A Zabolian, H Saleki, ... Biomedicine & Pharmacotherapy 141, 111824, 2021 | 133 | 2021 |
| AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation M Entezari, D Hashemi, A Taheriazam, A Zabolian, S Mohammadi, ... Biomedicine & Pharmacotherapy 146, 112563, 2022 | 132 | 2022 |
| Curcumin in cancer therapy: A novel adjunct for combination chemotherapy with paclitaxel and alleviation of its adverse effects M Ashrafizadeh, A Zarrabi, F Hashemi, ER Moghadam, F Hashemi, ... Life sciences 256, 117984, 2020 | 122 | 2020 |
| Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression M Ashrafizadeh, S Mirzaei, MH Gholami, F Hashemi, A Zabolian, M Raei, ... Carbohydrate polymers 272, 118491, 2021 | 121 | 2021 |
| Biomedical application of chitosan-based nanoscale delivery systems: Potential usefulness in siRNA delivery for cancer therapy M Ashrafizadeh, M Delfi, F Hashemi, A Zabolian, H Saleki, M Bagherian, ... Carbohydrate Polymers 260, 117809, 2021 | 120 | 2021 |
| Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects AJ Abadi, S Mirzaei, MK Mahabady, F Hashemi, A Zabolian, F Hashemi, ... Phytotherapy Research 36 (1), 189-213, 2022 | 118 | 2022 |
| Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects S Mirzaei, MH Gholami, F Hashemi, A Zabolian, MV Farahani, ... Drug Discovery Today 27 (2), 436-455, 2022 | 110 | 2022 |
| Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance S Mirzaei, AT Mohammadi, MH Gholami, F Hashemi, A Zarrabi, ... Pharmacological research 167, 105575, 2021 | 110 | 2021 |
| The long and short non-coding RNAs modulating EZH2 signaling in cancer S Mirzaei, MH Gholami, K Hushmandi, F Hashemi, A Zabolian, I Canadas, ... Journal of hematology & oncology 15 (1), 18, 2022 | 108 | 2022 |
| Lung cancer cells and their sensitivity/resistance to cisplatin chemotherapy: Role of microRNAs and upstream mediators M Ashrafizadeh, A Zarrabi, K Hushmandi, F Hashemi, ER Moghadam, ... Cellular signalling 78, 109871, 2021 | 105 | 2021 |
| Role of microRNA/epithelial-to-mesenchymal transition axis in the metastasis of bladder cancer M Ashrafizadeh, K Hushmandi, M Hashemi, ME Akbari, P Kubatka, ... Biomolecules 10 (8), 1159, 2020 | 104 | 2020 |
| NF‐κB as a regulator of cancer metastasis and therapy response: A focus on epithelial–mesenchymal transition S Mirzaei, S Saghari, F Bassiri, R Raesi, A Zarrabi, K Hushmandi, G Sethi, ... Journal of cellular physiology 237 (7), 2770-2795, 2022 | 91 | 2022 |
| Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response M Ashrafizadeh, MDA Paskeh, S Mirzaei, MH Gholami, A Zarrabi, ... Journal of Experimental & Clinical Cancer Research 41 (1), 105, 2022 | 89 | 2022 |
| Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention S Mirzaei, MDA Paskeh, E Okina, MH Gholami, K Hushmandi, M Hashemi, ... Journal of Experimental & Clinical Cancer Research 41 (1), 214, 2022 | 87 | 2022 |
| AIE-featured tetraphenylethylene nanoarchitectures in biomedical application: Bioimaging, drug delivery and disease treatment KSS Kumar, YR Girish, M Ashrafizadeh, S Mirzaei, KP Rakesh, ... Coordination Chemistry Reviews 447, 214135, 2021 | 85 | 2021 |
| Polychemotherapy with curcumin and doxorubicin via biological nanoplatforms: enhancing antitumor activity M Ashrafizadeh, A Zarrabi, F Hashemi, A Zabolian, H Saleki, M Bagherian, ... Pharmaceutics 12 (11), 1084, 2020 | 83 | 2020 |
Amir Reza ArefSVP Translational Sciences, Xsphera Biosciences INC. Dana-Farber Cancer InstituteVerified email at xspherabio.com
